Jointly develop long-acting HIV combination therapy Gilead and Merck reach cooperation

Today, Gilead Sciences and MSD jointly announced that they have reached an agreement to jointly develop and promote long-acting HIV combination therapies.

With the development of anti-HIV therapy, most HIV-infected people have been able to achieve the effect of controlling the virus level by taking daily anti-viral therapy.

Islatravir is an innovative NRTTI developed by Merck.

Lenacapavir is an innovative capsid inhibitor developed by Gilead Sciences, which can interfere with the assembly and disassembly of the HIV virus capsid protein.

According to the agreement, Merck and Gilead Sciences will jointly develop an oral or injectable long-acting HIV combination therapy consisting of islatravir and lenacapavir.

Note: The original text has been deleted

Reference materials:

[1] Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV.

[2] Merck Announces HIV Collaboration with Gilead.